65,437 trials
Mild Cognitive Impairment
Primary: Correlation Between Cognition Level Changes as Evaluated by Current Clinical Tools (i.e. MMSE) and Brain Activity Features Extracted Using the Neurosteer Technology…
Abdominal Aortic Aneurysm
Primary: Annual Aneurysm Growth Rate Between Patients With and Without Micro Bubble Uptake — 3.0; 3.2 mm/year
Herpes Zoster
Primary: Anti-glycoprotein E (gE) Antibody Concentrations Expressed as Geometric Mean Concentrations (GMCs) in HZ/suSeq and HZ/suCoAd Groups, and Between-group Ratios — 47434.82…
Sleep Disordered Breathing · Obstructive Sleep Apnea · Snoring
Primary: Change in Number of Subjects Without Oxygenation Abnormalities — 12; 10 Participants — p=0.54
Autism Spectrum Disorder
Primary: Child Externalizing Behavior Problems as Evidenced by Reductions in the Externalizing Scores on a Standardized Parent-report Questionnaire. — 68.40; 66.49 t-scores
Atrial Fibrillation · Atrial Flutter
Primary: Time From Initiation of Sedation to Full Recovery — 7.6; 5.5 minutes
Healthy
Primary: Percent Target Occupancy for JAK3 — 0.00; 0.00; 72.41; 28.74 percentage of occupancy
Type 1 Diabetes
Primary: Percentage of Time <70 mg/dL — 2.8; 2.1 Percent Time in Range
Prostate Cancer · Prostate Adenocarcinoma
Primary: Number of Participants With Adverse Events — 0 Participants
Macular Degeneration
Primary: Change in Best Corrected Visual Acuity (BCVA) — 4.57; 6.37 Letters
Pulmonary Disease, Chronic Obstructive
Primary: All-cause Health Care Resource Utilization — 32.54; 32.91; 17.80; 17.57 visits/year — p=0.639
Type 1 Diabetes Mellitus
Primary: Proportion of Subjects With Severe Hypoglycemia — 0 Participants
POEMS Syndrome
Primary: Treatment Success — 0 Participants
Obesity, Overweight
Primary: Body Mass Index — 39.12; 40.48 kg/m2
Rheumatoid Arthritis
Primary: Minimum Observed Plasma Concentration (Cmin) Post 10 Weeks of Certolizumab Pegol Dosing — 24.93 micrograms per milliliter (ug/mL)